Document is current
Any future updates will be listed below
-
Authors
,
-
Funding
Funding for this research was provided by:
National Institute for Health Research (10/71/01)
- License Information
-
More Information
Article History
Received: 18 October 2019
Accepted: 25 February 2020
First Online: 9 April 2020
Ethics approval and consent to participate
: Ethical approval was granted by the East of Scotland NHS Research Ethics Committee (approval 12/ES/0023); the trial was also approved by the UK Medicines and Healthcare Regulatory Authority (EudraCT number 2011-005271-16; Clinical Trial Authorisation number 41692/0001/001-0001). All participants provided written informed consent prior to participation.
: Not applicable
: All authors have completed the ICMJE uniform disclosure form at and declare no support for the work beyond funding of the trial by the NIHR HTA programme and infrastructure support detailed in the “Acknowledgements” section. Professor Donnan is a member of the New Drugs Committee of the Scottish Medicines Consortium and has received recent grants from Gilead Sciences and Shire Pharmaceuticals. Dr. Basnayake currently works for Fresenius Medical Care UK. Dr. Kirk currently works as a clinical director for MyMHealth. The other authors declare that they have no competing interests.
